A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers. Traditional cancer treatments such as chemotherapy and radiotherapy come with a serious disadvantage: they cannot distinguish cancer cells from normal cells. Since normal cells can be stunted by chemotherapy and destroyed by radiation along with abnormal cells, patients may experience serious health issues during a course of extended treatment…

View post:
Scientists Are "Reolysin" The Power Of Live Biologics To Fight Cancer In Two Recent Studies

You may also like:

• Over 20 Senior Level Speakers Will Gather At MDDexec’s European Sales And Marketing Summit, 17-18 March 2010, London
• Speeding The Path To Regulatory Approval In The Era Of Electronic Submissions
• Charities Urge Swift Action On Lung Health Blueprint, UK
• Ipsen Establishes Optimal Biological Dose For BN83495 Steroid Sulphatase (STS) Inhibitor In ER-Positive Metastatic Breast Cancer
• Nearly 4 Million Californians Report Sexual Or Physical Violence From A Spouse Or Companion
• Synta Presents STA-9090 NSCLC Data At The IASLC 10th Annual Targeted Therapies Of The Treatment Of Lung Cancer Meeting
• NHS Providers Should Open Their Books To Public Scrutiny, UK
• Starving the colon cancer cells
• Cancer Vaccines Led To Long-Term Survival For Patients With Metastatic Melanoma, Study Shows
• Bradley R. Straatsma, MD, JD Named 2010 American Academy Of Ophthalmology Laureate